Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03624543 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 30, 2026 → Nov 30, 2026
See other at-risk trials from Canadian Cancer Trials Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
    • Eligibility criteria expanded, about 39 words
  2. Primary completion date: Dec 31, 2025 to Jun 30, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v26
  3. Primary completion date: Jun 30, 2025 to Dec 31, 2025v25
  4. Primary completion date: Dec 31, 2024 to Jun 30, 2025v24
  5. Re-verified, no change to tracked fieldsv23
Show 21 earlier versionsHide 21 earlier versions
  1. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Study completion date: Jun 30, 2024 to Dec 31, 2025
    v22
  2. Primary completion date: Jun 30, 2023 to Dec 31, 2023
    • Start date: Dec 21, 2018 to Feb 14, 2019
    • Study completion date: Jun 30, 2023 to Jun 30, 2024
    v21
  3. Primary completion date: Dec 31, 2022 to Jun 30, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 72 to confirmed 51
    • Site details revised at 6 of 6 sites
    v20
  4. Primary completion date: Sep 30, 2022 to Dec 31, 2022
    • Study completion date: Jan 1, 2023 to Jun 30, 2023
    v19
  5. Study completion date: Sep 30, 2022 to Jan 1, 2023v18
  6. Primary and study completion dates: Sep 30, 2021 to Sep 30, 2022
    • Site contacts updated at 1 of 6 sites
    v17
  7. Study sites: 5 to 6v16
  8. Site details revised at 2 of 5 sitesv15
  9. Eligibility criteria expanded, about 39 wordsv14
  10. Site details revised at 1 of 5 sitesv13
  11. Primary and study completion dates: Dec 31, 2020 to Sep 30, 2021v12
  12. Primary completion date: Jul 31, 2020 to Dec 31, 2020v11
  13. Re-verified, no change to tracked fieldsv10
  14. Primary completion date: Jul 30, 2020 to Jul 31, 2020v9
  15. Eligibility criteria shortened, about 1 wordv8
  16. Study sites: 4 to 5v7
  17. Eligibility criteria expanded, about 66 words
    • Secondary endpoints revised (4)
    v6
  18. Study sites: 3 to 4v5
  19. Study sites: 2 to 3v4
  20. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 30, 2018 to Dec 21, 2018
    v3
  21. Start date: Aug 30, 2018 to Dec 30, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage.
Trial Details
NCT Number NCT03624543
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov